EGFR and Miyoshi myopathy: Considering the involvement of aberrant ErbB signaling in MM [32, 55] and the evidence that ErbB receptors levels are regulated, among the other mechanisms, via proteasomal degradation [56, 57], we also investigated whether Bor treatment could affect the expression of EGFR and ErbB2 and the activation of downstream pro-survival signaling effectors.